| Autor: |
R. Pettengell, Anthony H. Goldstone, R K Gupta, J. Hughes, K. E. Summers, Barry W. Hancock, R. A. Popescu, T. A. Lister, Ama Z. S. Rohatiner, David Cunningham, Peter Johnson, J.W. Sweetenham, James M. Foran, E M Bessell |
| Rok vydání: |
2000 |
| Předmět: |
|
| Zdroj: |
British Journal of Haematology. 109:81-88 |
| ISSN: |
0007-1048 |
| DOI: |
10.1046/j.1365-2141.2000.01965.x |
| Popis: |
Follicular lymphoma (FL) cells express CD20 and are associated in most cases with the t(14;18) chromosomal translocation. A multicentre study was undertaken between January 1997 and January 1998 to assess the complete response rate (CR) and overall response rate (RR) to rituximab, a chimaeric anti-CD20 monoclonal antibody. Seventy patients with previously treated FL received rituximab (375 mg/m2/week x4, by intravenous infusion). Restaging studies were performed 1 and 2 months after therapy. Molecular monitoring for the presence of cells harbouring the Bcl-2/JH gene rearrangement in the peripheral blood (PB) and bone marrow (BM) was performed before and after treatment using a two-step semi-nested polymerase chain reaction (PCR) assay. The overall RR was 32/70 (46%), being highest in patients who had received only one previous treatment (12/15, 80%). However, only two patients achieved a CR. The median duration of response was 11 months. Thirteen of 21 evaluable 'PCR-positive' patients (62%) became 'PCR-negative' in PB and/or BM samples 1 month after rituximab, although this did not correlate with clinical response. Treatment was generally well tolerated, although one patient developed Stevens-Johnson syndrome. Rituximab was shown to be active in FL, and in some cases PB and/or BM became PCR negative. Studies in combination with cytotoxic chemotherapy to increase the CR rate are warranted. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text